Question 1

What are the potential benefits of combining atezolizumab with SBRT for my specific situation?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer clinical trial (NCT03614949). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options I might have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer clinical trial (NCT03614949). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from this combination treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer clinical trial (NCT03614949). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer clinical trial (NCT03614949). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will be done to check my progress during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer clinical trial (NCT03614949). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs or logistical issues I should be aware of if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer clinical trial (NCT03614949). Contact the study team or your healthcare provider for specific answers.

What this study is about